Robbins Geller Wins Litigation Firm of the Year: Class Action at The National Law Journal’s Elite Trial Lawyers Awards
On July 14, 2022, Robbins Geller Rudman & Dowd LLP was named Litigation Firm of the Year in the Class Action category at The National Law Journal’s Elite Trial Lawyers Awards. The annual event recognizes “outstanding plaintiffs-side legal work” from the previous year.
This is the sixth year the Firm’s work has been recognized as Elite Trial Lawyers by The National Law Journal and the second year in a row the Firm was recognized for its groundbreaking work on class action cases.
In 2022, the Firm was also ranked number one in the nation by Institutional Shareholder Services’ Securities Class Action Services for recovering nearly $1.9 billion for investors last year alone, as Plaintiff Firm of the Year at the Benchmark Litigation West Coast Awards, top ranking from Chambers for the thirteenth consecutive year, and Tier 1 ranking (the highest available) from The Legal 500.
In addition to recovering more investor money lost to securities fraud than any other law firm, Robbins Geller continues to play a leading role in the nationwide effort to hold all facilitators of the prescription opioid public health crisis – manufacturers, distributors, and dispensers among others – accountable in In re National Prescription Opiate Litigation. A $26 billion settlement with three major distributors and manufacturer Johnson & Johnson was recently finalized after being negotiated last year. Paul J. Geller, managing partner of the Firm’s Boca Raton office, currently serves on the Plaintiffs’ Executive Committee and played a key role in negotiating the settlement.
San Francisco partner Aelish Marie Baig served as co-trial counsel in a recently concluded bellwether trial on behalf of the City and County of San Francisco. The case alleges that manufacturer, distributor, and pharmacy defendants substantially contributed to the epidemic that is ravaging the Bay Area. Last week, a groundbreaking combined $58 million settlement with the Teva and Allergan family of defendants was announced on the morning of closing arguments.
Robbins Geller also played a leading role as co-lead counsel in the prosecution of In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices & Antitrust Litigation, which concluded with a $609 million recovery. The antitrust case alleged that manufacturer Pfizer and marketer and distributor Vitaris (formerly Mylan) excluded competitors who manufactured and distributed generic alternatives for the life-saving EpiPen device from the market, reaping outsize profits from inflated prices paid by consumers and third-party payors.
The announcement of 2022 Elite Trial Lawyers winners from The National Law Journal is available here: https://www.law.com/nationallawjournal/2022/07/15/celebrating-excellence-at-the-2022-elite-trial-lawyers-awards/.
About Robbins Geller
Robbins Geller Rudman & Dowd LLP is one of the world’s leading complex litigation firms, representing plaintiffs in securities fraud, shareholder derivative, antitrust, corporate takeover, and consumer fraud and privacy cases. With 200 lawyers in 9 offices, Robbins Geller is one of the world’s largest plaintiffs’ firms, and the Firm’s attorneys have obtained many of the largest securities, antitrust, and consumer class action recoveries in history.
The Firm is ranked #1 on the 2021 ISS Securities Class Action Services Top 50 Report for recovering nearly $2 billion for investors last year alone – more than triple the amount recovered by any other plaintiffs’ firm. The Firm secured the largest-ever securities fraud class action settlement — $7.2 billion — in In re Enron Corp. Securities Litigation.
For media inquiries, please contact firstname.lastname@example.org or call (619) 338-3821.
Read More Firm News
- February 16, 2024
- February 16, 2024
- February 15, 2024
- From the Bench to Plaintiffs Bar: Why Judge Sam Sheldon Switched Gears to Rep Investors in Fraud Cases at Robbins GellerFebruary 14, 2024
- February 9, 2024